Product logins

Find logins to all Clarivate products below.


Chronic pain is a broad term encompassing many nociceptive, inflammatory, and neuropathic pain subtypes that can result from complex mechanisms affecting multiple pathophysiological pathways in the peripheral and central nervous systems; such complexity leads to difficulty for physicians in determining the mechanisms causing pain and, consequently, in finding an effective treatment for each patient. Primary care physicians and pain specialists use several drug classes, including antiepileptics, antidepressants, NSAIDs, and opioid analgesics, largely in an escalating sequence to provide adequate analgesia to patients, each of whom responds differently to available therapies based on individual pain etiologies. Opioid analgesics remain the class leader in treating chronic pain, although recent efforts in the United States to curb problems with overprescribing of opioid analgesics and to reduce the risk of abuse/misuse associated with these therapies have had a small but steadily growing impact on prescribing of this class for chronic pain patients with a history of, or at high risk of, abuse.

Related Market Assessment Reports

Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…